

Medication Assisted Treatment (MAT) Standards Webinar Series

Session 1

Connections, Reflections & Progress

21 April 2023 11am - 12.30pm

#HISMAT

Improvement Hub

Enabling health and social care improvement

Welcome

Ruth Robin Portfolio Lead





Agenda

Time	Agenda item	Speaker		
11.05-11.10	Welcome and introductions Programme Overview	Ruth Robin, Portfolio Lead, Healthcare Improvement Scotland		
11.10- 11.15	A note from the Scottish Government	Elena Whitham, Minister for Drugs & Alcohol Policy, Scottish Government		
11.15-11.25	Non-Fatal Overdose Pathway, Scottish Ambulance Service	Julie Heslin-McCartney, Clinical Effectiveness Lead (East Region), Scottish Ambulance Service		
11.25-11.35	DARS Caithness Project, NHS Highland	Lesley Campbell, Drug and Alcohol Recovery Service Team Lead, Caithness and Sutherland, NHS Highland		
11.35-11.40	Questions for speakers	All		
11.40-12.00	Breakout Session: The year ahead – ambitions and priorities	All		
12.00-12.10	The WAND Initiative, NHS Greater Glasgow & Clyde	John Campbell, Injection Equipment Provision Manager, NHS Greater Glasgow & Clyde		
12.10-12.20	Multiple Pathways to Recovery, SISCO	Natalie Logan Maclean, CEO, SISCO		
12.20-12.25	Questions for speakers	All		
12.25-12.30	Next Steps & Close	Ruth Robin		

A note from the Scottish Government



Elena Whitham
Minister for Drugs & Alcohol Policy



Julie Heslin-McCartney
Clinical Effectiveness Lead (East Region),
Scottish Ambulance Service










SCOTTISH DRUG DEATHS TASKFORCE

Contribute to a national programme that allows every person in Scotland at risk of experiencing or witnessing NFOD to have access to Naloxone in an emergency situation and receive post incident support



SCOTTISH DRUG DEATHS TASKFORCE

MAT Standard 3:

All people at high risk of drug-related harm are proactively identified and offered support to commence or continue MAT

Medication Assisted Treatment (MAT) Standards for Scotland

Access, Choice, Support



Legal Position – Data Protection Impact Assessment



UK GDPR Article 6(1)(e):

the processing is necessary to perform a task in the public interest or for official functions, and the task or function has a clear basis in law.


UK GDPR Article 9 (2)(h):

the processing is necessary for medical diagnosis, the provision of health or social care or treatment or the management of health or social care systems and services. For the purposes of Section 10(2) of The Data Protection Act 2018 (and acknowledging the strict obligations of confidentiality at SAS), this situation meets the requirements of Paragraph 2 of Part 1 of Schedule 1 of the Data Protection Act 2018

Section 2A of The National Health Service (Scotland) Act 1978

to promote the improvement of the physical and mental health of the people of Scotland. The processing foreseen in this DPIA involves SAS exercising a function conferred on it by legislation, thus meeting the requirements of Section 8 of The Data Protection Act 2018.


Non-Fatal Overdose Pathway – Flag Criteria & Response



Consideration of non-fatal overdose data sharing objections

- Patient consent to share data is obtained on scene.
- If they don't give consent or are unable to consent, this is registered as on objection.
- All objections are considered and can be over-ruled where there is evidence of clear risk to life.
- ✓ Decreased Level of consciousness on crew initial assessment?
- ✓ Respiratory rate <10</p>
- √ Seizure
- ✓ Is there evidence of previous episodes of overdose or escalating risk to loss of life?
- ✓ Did the episode of care conclude with no conveyance and significant safety netting concerns?

Non-Fatal Overdose Pathway – Incidents Reported 01.07.21 to 31.01.2023



Outcomes and Measurement

Data definition

Can this be broader?

Is it working as intended?

Can we capture a wider 'at risk' population?

Re-design of electronic patient recording form

How does this evolve to suit changing landscape of drug use?

Injecting harms

Cocaine

Gabapentinoids

Problematical alcohol use

MAT Standards / MIST / Scottish Government

Work together to seek to understand the outcomes for patients

Measure the impact on prevention of harm and reduction in deaths



DARS Caithness Project, NHS Highland


Lesley Campbell

Drug and Alcohol Recovery Service Team Lead, Caithness and Sutherland, NHS Highland





Caithness DARS MAT 3 Project



A warm hearted welcome to Caithness! Duncansby Halkirk Altnabreac Dundee Perth • Kinbrace **Edinburgh** Lanark Dumfries

Population 25,347

Concerns regarding population health and mortality

Number of deaths > births


- SIMD 2020 identifies 4 data zones in the 20% most deprived in Scotland
- 9.6% of the working-age are employment deprived
- NRS data shows most people in Caithness die over the age of 60 however there is a male death spike age 30-44
- CDARS average 170 referrals per year and hold 90-100 on caseload at any time
- 40% of these are on OST

Model for Improvement

What are we trying to accomplish?

How will we know that a change is an improvement?

What change can we make that will result in improvement?



(WIGH RISK OF DRUG RELATED HARM

REFERENCE TRISGER CHECKLIST

hane:

008/04

Abbress-

Contact frumber -


Initial Screening Question -	Y	14
00 YOU USE DRUGS REGULARLY?		
DO YOU USE MORE THAN ONE TYPE OF DRUG INCLUDING ALCOHOL AT THE SAME		

If yes continue to ask -		
HAVE YOU SEEN IN PRISON OF POLICE CUSTODY IN THE LAST 6 MONTHS?		
HAVE YOU EVER RECEIVED THREATS PROM OTHERS BECAUSE OF DRUGS?		
HAVE YOU EVER HAD A NON-FATAL OVERDOSE?		
DO YOU DRINK ALCOHOL REGULARLY?		
DO YOU LIVE ALONE OR ARE YOU HOMELESS?		
DO YOU HAVE ANY MENTAL HEALTH PROBLEMS OR HAVE YOU EVER BEEN REFERRED TO MENTAL HEALTH SERVICES?		Г
DO YOU HAVE ANY PHYSICAL REALTH PROBLEMS THAT YOU TAKE MEDICATION INCLUDING THALERS REQULARLY FOR?	П	Г
HAUE YOU BEEN IN HOSPITAL OR REHAB IN THE LAST & MONTHS?		
HAS THERE BEEN ANY RECENT SIGNIFICANT EVENTS WHICH HAVE BEEN DISTRESSING FOR YOUR		Г
It would be useful (but not essential) for us to also known	_	_
ARE YOU SUPPERING FROM OR HAVE YOU PREVIOUSLY SUPPERED FROM WITHORANIAL SYMPTOMS?		Г
HAVE YOU EVER EXPERIENCED VIOLENCE FROM A PARTNER?		
ARE YOU PREGNANT?		
DO YOU HAVE ANY DIFFICULTIES READING OF WRITING?	$\overline{}$	
HAVE YOU EVER SERVED IN HIM ARMED FORCES?		

Completed on (SMN)

thi (name)

From (service)



Digital Value Management Board

3



uring the MAT 3 and 4 proje rendered X. "Will people at high ri Building cases by within team we aim to improve overail of drug-relead hern are by understanding where west roactively identified and offered eriofaction with the Calthnes is. Staff are concerned about DARS service. We will pgent to commence or contin change of role resulting in loss Mat", in projects reduce thus therefore measure staff and of patisfaction. related harms' death and to offer patient experience. null standard 4: harm reduction test notification of NFCO/DRO Process messure: Staff referral numbers current esperience delly using limp ersus new and uptake of MA Neverlant - % satisfaction 4 and MAT L Process ore to monitor improveme Capacity assessment to be measures no of Trigger with qualitative data to completed by all staff over a 2 checklist referrers, No. of nderstand. Process measure week period prior to project Patient experience from each and again at quarterly previously known versus new and hospital Easter numbers. deraction using Jigsaw place intervals. brancing measures: Beterni number of feedbacks will be monitored along with to assessment waiting times, numbers outing out, staff and publishes data to understan patient algerience. TAM zwiles swinew trees 5.4 data during assentive out reach process. Other data All staff splints patient experience All staff to complete capacity collected via statutory means date, all profit report in staff tools individually and team.

Picture with thanks to Institute for Healthcare Improvement 2023

Α	В		BA	BB	BC	BD	BE	BF	
	% of success - staff lunch breaks				25%		95%	100%	A
S	% of patient feedback (weekly)								
asure	Days since DRD/NFOD notification (weekly reporting from Scrum note)	25	32	39	46	53	60	67	
Meas	Referral numbers (monthly)		14				9		
8	Referral to Assessment waiting time (quarterly)								
č	Trigger checklist referrals (weekly initially)	2	2	1	4	1	1	1	
Performa	% of new/ not previously known people (weekly initially)	0%	0%	0%	0%	0%	0%	0%	
F.	% Harm redution uptake (weekly initially)	0%	0%	0%	25%	0%	0%	100%	
<u>a</u>	% Opting out of assertive outreach (weekly initially)	0%	0%	0%	0%	0%	0%	0%	
	% going on to MAT 1 from trigger checklist referral (quarterly)	0%	0%	0%	0%	0	0	100%	
	% of direct patient care (quarterly)	0%							
≥ ĕ	% of indirect patient care (quarterly)	0%							
Capacity Measure	% of staffing establishment in post	8%	88%	88%	88%	88%	88%	88%	
S s									¥
		4							Þ
> =	Measurement Plan Box Score Quality QPDSA Safety Page 1	tient	Experience	Staff Experience	Staff Experience	:e			

Partners

Who are our partners? Strengths of a rural community **Barriers**

Communication Networking **Sharing** Educating





tackle addiction problems

WORR than To proper from a range of the property of the proper







There are always challenges along the way!







THE CALDICOTT PRINCIPLES

- 1 Justify the purpose(s) for using confidential information.
- 2 Use confidential information only when it is necessary.
- 3 Use the minimum necessary confidential information.
- 4 Access to confidential information should be on a strict need-to-know basis.
- 5 Everyone with access to confidential information should be aware of their responsibilities.
- 6 Comply with the law.
- 7 The duty to share information for individual care is as important as the duty to protect patient confidentiality.
- 8 Inform patients and service users about how their confidential information is used.

- 1- Can we justify the purpose?
- 2- Is it necessary?
- 3- Are we collecting minimal information?
- 4- Is it need to know information?
- 5- Is my team aware of their responsibilities?
- 6- Am I complying with the law?
- 7- Is the duty to share more important than confidentiality?

The story so far . . .





The potential!



2023 1st May

Questions for speakers

Julie Heslin-McCartney
Clinical Effectiveness Lead
(East Region)
Scottish Ambulance Service

Email: julie.mccartney2@nhs.scot

Lesley Campbell

Drug and Alcohol Recovery

Service Team Lead

Caithness and Sutherland, NHS Highland

Email: lesley.campbell6@nhs.scot

Breakout session: The year ahead – ambitions and priorities

Questions to consider

- What are your high-level local priorities going into the next year?
- What will be your most significant barriers to progress in the next year?
- What will be your strongest enablers in the next year?
- What further national support would be helpful to you in the coming year?

The WAND Initiative, NHS Greater Glasgow & Clyde

John Campbell

Injection Equipment Provision Manager, NHS Greater Glasgow & Clyde




WAND

from idea to implementation

John Campbell

History of drug harms in Glasgow

- 1986 Benzo harm (Temazepam)
- 1990's Hep C and rising DRD's
- 2000 Clostridium
- 2009 Anthrax
- 2011 Newer type benzos
- 2015 Botulism
- 2015 HIV
- 2019 Record DRD
- 2020 increase in injecting injuries?



"Just a minute!"

WAND

- WAND is a multi-agency coordinated harm reduction response
- Focuses on interventions carefully selected to reduce most significant drug harms – DRD, BBVs and Injecting complications
- Incentivised to drive footfall















AIR

- AIR tool is a comprehensive assessment tool which has been designed to be used as a key component of the WAND initiative.
- The tool is accessed through the main NEO
 360 system and available to trained staff
- This tool guides both parties through the assessment process. This involves in depth discussions regarding all aspects of the preparation and injection of drugs.
- This is not a survey, research or data collection tool

ASSESSMENT OF INJECTING RISK JMC22/11/1983 (M), AGE 39

▶ INFORMATION This NEO module is designed to assist experienced IEP staff conduct an assessment of injecting risk. This assessment should be used in an interactive way to promote discussion and engagement. It has been designed to improve our response when providing a service tonse injecting street drugs. It will have limited use with those injecting IPEDs. Suidance for staff Promote less risky injecting stees if possible. Promote less risky injecting stees if possible. Promote route transition, such as smoking, if possible. Provide Nationar and overdose awareness if appropriate Offer condoms, if drugs are used for sexual enhancement. Red = high risk of overdose

	Injected	Smoked	Swallowed	Othe
Heroin				
Methadone (Street)				0
Methadone (Prescribed)	0	0	0	
Buprenorphine / Suboxone (Street)			0	
Buprenorphine / Suboxone (Prescribed)				
Benzodiazepines (Street)				
Benzodiazepines (Prescribed)				
Alcohol				
Pregabalin (Prescribed)	0			
Pregabalin (Street)				
Gabapentin (Prescribed)				
Gabapentin (Street)				
Cocaine Powder				
Cocaine Freebase / Crack	0			
Cocaine and Heroin (Snowball)	0			
Amphetamine			0	
Methamphetamine				
New Psychoactive Substance Stimulant Type (NPS)				
Steroids (IPEDS)				
Growth Hormone (IPEDS)	0		0	
Tanning Agents / Melanotan (IPEDS)				
Other				

WAND only happened because......

- A national AIR tool was developed in partnership with other board areas
- We had maximum buy in from our third sector partners management
- There was a willingness from frontline staff to drive the initiative forward
- We provided advanced training for all WAND staff
- We had full support from our ADP including a leap of faith with incentivised cash payments

Four stages to WAND implementation



Acknowledgement harm reduction needs improved



Train staff to the level where they are HR competent



Implement the initiative with maximum support



Monitor, feedback, improve and develop



An example of WAND driving change

Injection Site	Number (Value)	Number (%)
Arms	618	52
Legs	284	24
Groin	518	43
Neck	22	1



Thank you

Multiple Pathways to Recovery, SISCO

Natalie Logan McClean CEO, Sustainable Interventions Supporting Change Outside (SISCO)




SISCO

- Sustainable
- Interventions
- Supporting
- Change
- Outside



What makes SISCO unique?



Supporting the many pathways of recovery







INTERVENTION

PSYCHOSOCIAL SUPPORT


LIFE SKILLS





ORT

RECOVERY SUPPORTS



Over the years we have built strong working relationships with a number of vital organizations who offer prisoners support prior to liberation.

Some of these partners include:

Scottish Prison Service

Street Soccer Scotland

Community Justice Scotland

The Violence Reduction Unit

UWS

Dynamic Creations

Strathclyde University

Phoenix Futures

NRFG

G20

NG Homes



Cost Comparison

	Cost*
Cost to house a prisoner for a year including legal costs	£,64,000
2017 cost in court cases	£700 million
Average custodial sentence 9 ½ months	£30,083
Community payback orders in 2018 for 19,000 people	£37.4 million
An individual service 15 years following high court trial	£640,000
HTC monitoring tag	£126 p/w

The average cost to house a prisoner yearly is **£38,000.**

With legal costs of £26,000 this can rise to £64,000. The average cost to place someone in a residential rehab with aftercare support for a year is £25,728. This represents saving the taxpayer of £38,272. One peer mentor would support 6 prisoners at a salary cost of £22,000 per year.

This represents saving the taxpayer £362,000 per year to the criminal justice budget.

Using statistics available from HMP Barlinnie from 2017/18, we successfully supported the liberation of 38 prisoners by keeping them out of prison for a year saving the taxpayer £244,666.6666.

This was recognized by the Scottish Prison Service, and we won a partnership award for that year.

Questions for speakers

John Campbell
Injection Equipment Provision Manager,
NHS Greater Glasgow & Clyde

Email: John.Campbell@ggc.scot.nhs.uk

Natalie Logan McClean CEO, Sustainable Interventions Supporting Change Outside (SISCO)

Email: natalie@sisco.org.uk

Next steps and close

Ruth Robin
Portfolio Lead





Thank you



- Event summary to follow
- Provisional date for next webinar: Friday 9th June 2023

